I

nsys Therapeutics (INSY) agreed on Thursday to pay $500,000 to Massachusetts to resolve charges of illegally marketing its highly addictive Subsys painkiller and paying kickbacks to doctors to write prescriptions.

Between 2012 and 2014, state officials charged that Insys marketed Subsys for patients whose pain is caused by an ailment other than cancer, even though the medicine was only approved by regulators for treating cancer pain. And Insys made misleading statements suggesting that Subsys was appropriate for combating mild pain, even while citing a study that found the drug was only appropriate for “moderate to severe” pain.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X